Shubham Pant

MD, MD Anderson, US

Specializes in [Gastrointestinal Oncology]

• Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center
• Research studies have led to FDA accelerated approval of Zanidatamab for HER2 overexpressing biliary tract cancer and the incorporation of Adagrasib into the NCCN guidelines for KRAS G12C advanced pancreatic cancer and biliary tract cancer

tosprivacy